BMI, concomitant use of immunomodulators, rates of side effects, and laboratory markers, including serum albumin and CRP, are significantly associated with anti‐TNF‐α trough levels in IBD patients.43 The gene discussed is ALB; the disease is inflammatory bowel disease.